Medtronic plc, a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and in The New England Journal of Medicine.
Dear partners, We would like to inform you about the imminent release of an updated version of the VenaSeal vein closure system (internal code – VS-403)
We are glad to inform you about the availability for orders of pacemakers with cardiac resynchronization therapy(CRT-P) Percepta, Solara, and Serena by Medtronic.
